

Pfizer Records Reveal 23-Person Study of COVID Vaccine Booster Safety and Effectiveness Before Approval

By Judicial Watch Global Research, September 05, 2023 Judicial Watch 31 August 2023 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), click here.

Click the share button above to email/forward this article to your friends and colleagues. Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

Judicial Watch released <u>58 pages</u> of records from the U.S. Food and Drug Administration (FDA) showing that a Pfizer study surveyed 23 people in 2021 to gauge reactions to its COVID vaccine booster before asking the FDA to approve it. The FDA indicated that this production of records "represents our complete response to your request; no additional productions are anticipated."

The records were obtained in response to a March 2022 <u>lawsuit</u> filed after the Department of Health and Human Services failed to respond to an August 2021 Freedom of Information Act (FOIA) request for records "submitted by Pfizer and BioNTech to the FDA, including BARDA, relating to 'booster' vaccinations for the SARS-CoV-2 virus" (*Judicial Watch, Inc. v. U.S. Department of Health and Human Services* (No. 1:22-cv-00730)).



August 26, 2022

Via Email: Iburke@judicialwatch.org

Lauren M. Burke Judicial Watch, Inc. 425 Third Street, SW, Suite 800 Washington, DC 20024

Re: FDA FOIA Request 2021-5541; Judicial Watch, Inc. v. HHS, 22-cv-00730-RC

Dear Ms. Burke,

Pursuant to the Joint Status Report filed on July 12, 2022 in the above-referenced matter, attached please find our response to the Freedom of Information Act (FOIA) request number **2021-5541**. This production represents our complete response to your request; no additional productions are anticipated.

Attached are 58 pages of records from the FDA's Center for Biologics Evaluation and Research (CBER) (Bates numbered FDA-CBER-2021-5541-00001 to -00058) some of which contain redactions. We have withheld portions of four pages, and we are releasing 54 pages in full.

We have withheld portions of pages under Exemption (b)(6), 5 U.S.C. § 552(b)(6). That exemption protects information from disclosure when its release would cause a clearly unwarranted invasion of personal privacy. FOIA Exemption 6 is available to protect information in personnel or medical files and similar files. This requires a balancing of the public's right to disclosure against the individual's right to privacy.

Please direct any questions regarding this response to Assistant United States Attorney Marcia Sowles of the Department of Justice, at (202) 514-4960 or <u>Marcia.Sowles@usdoj.gov</u>.

Sincerely,

Ricci J. Ward -S Digitally signed by Reci J. Ward -S Date: 2022/08.36 (MIRS) 4 - 04707

Ricci Ward for Beth Brockner Ryan Chief, Access Litigation and Freedom of Information Branch Division of Disclosure and Oversight Management Office of Communication Outreach and Development Center for Biologics Evaluation and Research

Attachments

cc:

Marcia Sowles, Federal Programs Branch, USDOJ (By email) Leah Edelman, Office of the Chief Counsel, FDA (By email)

U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 w.ww.fda.gov



COVID-19 Vaccine (BNT162, PF-07302048)

BB-IND 19736

Phase 1 Booster Safety and Immunogenicity Data up to 1 Month Post-Dose 3 of BNT162b2 30 µg in Study C4591001

July 2021

PFIZER CONFIDENTIAL Page 1

FDA-CBER-2021-5541-00006

Click here to read the full report.

Biomedical Advanced Research and Development Authority, BARDA, has been heavily involved with the development of the COVID-19 vaccine. According to its <u>website</u>:

The Biomedical Advanced Research and Development Authority (BARDA) provides an integrated, systematic approach to the development of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies such as chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks; pandemic influenza (PI), and emerging infectious diseases (EID).

<u>BioNTech</u> is a German pharmaceutical company that partnered with Pfizer in developing the original vaccine.

The records include <u>a July study</u> titled "Phase 1 Booster Safety and Immunogenicity Data up to 1 Month Post-Dose 3 of BNT162b2 30 μ g [micrograms] in Study C4591001" provided "preliminary safety and immunogenicity data" for a group that had received two vaccine shots and, seven to nine months later, a third (booster) shot:

This submission includes preliminary findings from a subset of younger (18 to 55 years of age) and older (65 to 85 years of age) participants in the Phase 1 part of Study C4591001 who completed the initial two-dose series of BNT162b2 30 μ g, given approximately 3 weeks apart, and then received a third dose (booster) of BNT162b2 30 μ g approximately 7 to 9 months after the second dose. Data were collected through the cutoff date of 13 May 2021.

The participants were evaluated for symptoms up to one month after the booster shot. The booster's immunogenicity, or how well a vaccine works over time, was evaluated seven days and one month after the booster:

SARS-CoV-2 50% neutralization titers were assessed in sera drawn before BNT162b2 Dose 1 (on Day 1); 7 days and 1 month after BNT162b2 Dose 2; before Dose 3; and 7 days and 1 month after Dose 3.

The participants included 11 people aged 18 to 55 and 12 people aged 65 to 85. Of the younger group, there were nine females and two males; eight of whom were white, one was black and two were Asian. Of the older group six were female, six were males, and all were white.

The study reports that a booster dose increases the breadth of neutralizing response against SARS-CoV-2 variants and that the data suggests that a third dose could prolong protection and further increase the breadth of protection:

[T]he durability of protection from vaccination and the required frequency of booster doses are unknown at this time. To date, results from the global Phase 1/2/3 study of BNT162b2 indicate robust protection lasting at least 6 months, despite modest waning of immunity over time. Booster doses have the potential to keep protection high if immunity continues to decline over time.

This Pfizer study was sent to Marion Gruber, PhD, director of the Office of Vaccines Research and Review.

An August 13, 2021, FDA-CBER (Center for Biologics Evaluation and Research) <u>report</u> is titled "Phase 1 Booster (Dose 3) Immunogenicity at 1 Month Post-Dose 3 in Study C4591001: SARS-CoV-2 Wild-Type and Delta Variant Neutralization Data."

On August 24, 2021, the White House <u>stated</u> it was moving "aggressively" to roll out booster shots despite not yet receiving clearance from the FDA to give everyone third doses.

Shortly thereafter, it was <u>reported</u> that Gruber and her deputy, Phil Krause, were leaving the agency because they were frustrated with Centers for Disease Control (CDC) and Biden White House interference in vaccine decisions. <u>Gruber and Krause</u> were among a group of resigning doctors who agreed that "Available evidence doesn't yet indicate a need for COVID-19 vaccine booster shots among the general population ..."

On September 21, 2021, just over a month after Pfizer's second submission, the FDA <u>approved</u> a single booster dose of the Pfizer-BioNTech vaccine for those over 65, for those 18 to 64 at a high risk of severe Covid-19, and for those whose frequent institutional or occupational exposure puts them at high risk of serious complications of COVID-19.

The FDA said it based <u>its decision</u> on the documents presented by Pfizer, as well as input from the CDC, the Israeli Ministry of Health and the University of Bristol in the UK.

Three weeks after approval, about 8.9 million boosters had been administered.

"With the planned push for new boosters by the Biden administration, the public would do well to examine these troubling documents about the shotgun approval of prior COVID boosters," said Judicial Watch President Tom Fitton.

Through FOIA Judicial Watch has uncovered a substantial amount of information regarding COVID-19 issues:


- In July 2023, Judicial Watch <u>sued</u> DHS for records and communications between DHS component offices and the U.S. Biological Defense Program regarding a \$2 million grant awarded by the DHS's Ground Truth Network to EcoHealth Alliance, which is implicated in using tax dollars for "gain-of-function" coronavirus research at the Wuhan Institute for Virology and elsewhere in China.
- HHS records included the initial grant application and annual reports to the National Institutes of Health (NIH) from EcoHealth Alliance, describing the aim of its work with the Wuhan Institute of Virology in China to create mutant viruses "to better predict the capacity of our CoVs [coronaviruses] to infect people."
- HHS records included <u>emails</u> of then-Director of the National Institutes of Health (NIH) Francis Collins showing a British physicians' group recommended the use of Ivermectin to prevent and treat COVID-19.
- Heavily redacted HHS <u>records showed</u> that just two days prior to FDA approval of the Pfizer-BioNTech COVID-19 vaccine a discussion was held between U.S. and UK health regulators regarding the COVID shot and "anaphylaxis," with the regulators emphasizing their "mutual confidentiality agreement."
- HHS produced records regarding data Moderna submitted to the FDA on its mRNA COVID-19 vaccine, which indicated a "statistically significant" number of rats were born with <u>skeletal deformations</u> after their mothers were injected with the vaccine. The documents also revealed Moderna elected not to conduct a number of standard pharmacological studies on the laboratory test animals.
- In October 2020, Judicial Watch received FDA records that detailed <u>pressure</u> for COVID-19 vaccine booster approval and use.
- NIH records <u>revealed</u> an FBI "inquiry" into the NIH's controversial bat coronavirus grant tied to the Wuhan Institute of Virology. The records also showed National Institute of Allergy and Infectious Diseases (NIAID) officials were concerned about "gain-of-function" research in China's Wuhan Institute of Virology in 2016. The Fauci agency was also concerned about <u>EcoHealth Alliance's</u> lack of compliance with reporting rules and use of gain-of-function research in the NIH-funded research involving bat coronaviruses in Wuhan, China.
- HHS records revealed that from 2014 to 2019, <u>\$826,277</u> was given to the Wuhan Institute of Virology for bat coronavirus research by the NIAID.
- NIAID records showed that it <u>gave nine China-related grants to EcoHealth</u> <u>Alliance</u> to research coronavirus emergence in bats and was the NIH's top issuer

of grants to the Wuhan lab itself. The records also included an email from the vice director of the Wuhan Lab asking an NIH official for help finding disinfectants for decontamination of airtight suits and indoor surfaces.

- HHS records included an "urgent for Dr. Fauci " email chain, citing ties between the Wuhan lab and the taxpayer-funded EcoHealth Alliance. The government emails also reported that the foundation of U.S. billionaire Bill Gates worked closely with the Chinese government to pave the way for Chinese-produced medications to be sold outside China and help "raise China's voice of governance by placing representatives from China on important international counsels as high level commitment from China."
- HHS records included a grant application for research involving the coronavirus that appears to describe "gain-of-function" research involving RNA extractions from bats, experiments on viruses, attempts to develop a chimeric virus and efforts to genetically manipulate the full-length bat SARSr-CoV WIV1 strain molecular clone.
- HHS records showed the State Department and NIAID knew immediately in January 2020 that <u>China was withholding COVID data</u>, which was hindering risk assessment and response by public health officials.
- University of Texas Medical Branch (UTMB) records showed the former director of the Galveston National Laboratory at the University of Texas Medical Branch (UTMB), <u>Dr. James W. Le Duc</u> warned Chinese researchers at the Wuhan Institute of Virology of potential investigations into the COVID issue by Congress.
- HHS records regarding biodistribution studies and related data for the COVID-19 vaccines showed a key component of the vaccines developed by Pfizer/BioNTech, lipid nanoparticles (LNPs), were found <u>outside the injection site</u>, mainly the liver, adrenal glands, spleen and ovaries of test animals, eight to 48 hours after injection.
- Records from the Federal Select Agent Program (FSAP) revealed <u>safety</u> <u>lapses</u> and violations at U.S. biosafety laboratories that conduct research on dangerous agents and toxins.
- HHS records included <u>emails</u> between National Institutes of Health (NIH) then-Director <u>Francis Collins</u> and Anthony Fauci, the director of National Institute of Allergy and Infectious Diseases (NIAID), about hydroxychloroquine and COVID-19.
- HHS records showed that NIH officials <u>tailored confidentiality forms</u> to China's terms and that the World Health Organization (WHO) conducted an unreleased, "strictly confidential" COVID-19 epidemiological analysis in January 2020.
- Fauci <u>emails</u> included his approval of a press release supportive of China's response to the 2019 novel coronavirus.

*

Note to readers: Please click the share button above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.



The Worldwide Corona Crisis, Global Coup d'Etat Against

Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project "destroys people's lives". He provides a comprehensive analysis of everything you need to know about the "pandemic" — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

"My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the "deadly" COVID-19 "vaccine". This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument."

ISBN: 978-0-9879389-3-0, Year: 2022, PDF Ebook, Pages: 164, 15 Chapters

Price: \$11.50 FREE COPY! Click here (docsend) and download.

We encourage you to support the eBook project by making a donation through Global Research's <u>DonorBox "Worldwide Corona Crisis" Campaign Page</u>.

The original source of this article is <u>Judicial Watch</u> Copyright © <u>Judicial Watch</u>, <u>Judicial Watch</u>, 2023

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Judicial Watch

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in

print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca